A bald man with a mustache wearing a dark suit, light blue shirt, and patterned tie, smiling in front of a plain gray background.

Leslie Citrome, MD, MPH

Adjunct Professor of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

  • 70Articles
  • 459.8KReads1
  • 1996–2026Active
  • 201Collaborators
  • 1.3KCitations2
JCP
Safety and Tolerability of Initiating With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months
Original Research

Safety and Tolerability of Initiating With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months

February 28, 2024

In this post hoc analysis, treatment of acutely exacerbated schizophrenia with aripiprazole lauroxil or paliperidone palmitate was well tolerated, consistent with the safety profiles of these medications.
, , , et al
PCC
Alternative Treatment for Agitation in Schizophrenia and Bipolar Disorder
Narrative Review

Alternative Treatment for Agitation in Schizophrenia and Bipolar Disorder

January 30, 2024

While oral and intramuscular formulations of pharmacologic agents continue to be commonly used to treat acute agitation, novel agents with alternative routes of delivery are becoming available.
, , , et al
JCP
Lemborexant and Daridorexant in Insomnia: NNT, NNH, and LHH
Original Research

Lemborexant and Daridorexant in Insomnia: NNT, NNH, and LHH

October 2, 2023

This study examined whether differences existed between lemborexant and daridorexant in number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH)...
, ,
JCP
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg
Original Research

Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg

September 4, 2023

A new formulation of injectable aripiprazole for administration every 2 months showed similar rates of treatment-emergent adverse events to aripiprazole once-monthly 400 mg. Patients in both groups remained clinically...
, , , et al
JCP
Non-Dopaminergic Mechanisms for Schizophrenia Symptom Management
Educational Activity

Non-Dopaminergic Mechanisms for Schizophrenia Symptom Management

August 7, 2023

Next generation therapeutics that work well, are better tolerated, and lead to improved outcomes may offer a different treatment approach for patients with schizophrenia.
,
JCP
NNT, NNH, and LHH for Lumateperone
Original Research

NNT, NNH, and LHH for Lumateperone

March 6, 2023

The benefit-risk assessment of lumateperone was favorable as measured by number-needed-to-treat and number-needed-to-harm analyses.
, , , et al
JCP
Effect of Zuranolone on Anxiety and Insomnia in Postpartum Depression
Original Research

Effect of Zuranolone on Anxiety and Insomnia in Postpartum Depression

January 30, 2023

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived functional health in patients with PPD.
, , , et al
JCP
Impact-TD Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia
Consensus Statement

Impact-TD Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia

November 28, 2022

This easy-to-use scale developed by 7 experts measures the impact of TD on patients’ daily functioning.
, , , et al
JCP
Sublingual Dexmedetomidine for Agitation in Schizophrenia
Original Research

Sublingual Dexmedetomidine for Agitation in Schizophrenia

October 3, 2022

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or schizoaffective disorder.
, , , et al
JCP
Transdermal HP-3070 for Hostility in Schizophrenia
Original Research

Transdermal HP-3070 for Hostility in Schizophrenia

June 6, 2022

Schizophrenia is sometimes accompanied by aggressive, hostile behavior, particularly during the acute phase. This post hoc analysis of a phase 3 study examines the efficacy of transdermal asenapine (HP-3070)...
, , , et al
JCP
Educational Activity

TD Diagnostic and Treatment Fundamentals

October 12, 2021

Can you recognize risk factors for tardive dyskinesia? Are you familiar with diagnostic criteria? Do you regularly assess patients for the condition? Are you knowledgeable about using new medications...
,
JCP
Academic Highlights

Measurement-Based Care for Tardive Dyskinesia

August 31, 2021

Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
,

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Insightful. Evidence-based. Human-centered.

Listen Now
Psychiatrist Steven Berkowitz, MD, discusses psychedelic medicine for trauma treatment

Subscribe to read
more articles

Subscribe